Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review
Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA probably leads to lower pneumonia: high‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review
Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA probably leads to lower pneumonia: low‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in moderate to severe exacerbations: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LAMA (low certainty).
1 finding from 1 review
Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in severe exacerbations: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Death (all causes)
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to death due to any cause (absolute effect size estimates based… compared with ADT only (moderate certainty).
1 finding from 1 review
Adverse events grade 3 to 5 Range of
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher grade III to V adverse events compared with ADT only (low certainty).
1 finding from 1 review
Prostate cancer‐specific death5
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower prostate cancer‐specific death5 compared with ADT only (moderate certainty).
1 finding from 1 review
Time to progression
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to progression (absolute effect size estimates based on… compared with ADT only (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher discontinuation due to adverse events compared with ADT only (low certainty).
1 finding from 1 review
All adverse events
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher all adverse events compared with ADT only (low certainty).
1 finding from 1 review
Quality of life at 12 months (
1 finding from 1 review
Complete clearance · people with scabies, 5 to 80 years of ageLocation: Egypt, India
Oral ivermectin 200 μg/kg (1 to 3 doses) showed no clear difference in complete clearance ‐ week 1 compared with topical ivermectin 1% lotion/solution (1 to 3 applications) (low certainty).
3 findings from 1 review
RR 0.84 [0.65, 1.08]
1 study · 62 participants
Low
RR 1 [0.94, 1.06]
1 study · 62 participants
Moderate
RR 0.99 [0.95, 1.03]
2 studies · 272 participants
Moderate
Number of participants with ≥ 1 AE ‐ week 4 · people with scabies, 5 to 80 years of ageLocation: Egypt, India
It is very uncertain whether oral ivermectin 200 μg/kg (1 to 3 doses) changes number of participants with ≥ 1 AE ‐ week 4 compared with topical ivermectin 1% lotion/solution (1 to 3 applications) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with scabies, 5 to 80 years of ageLocation: Egypt, India
1 finding from 1 review
Complete clearance · people with scabies, over 5 years of ageLocation: India
Oral ivermectin 200 μg/kg (1 dose) showed no clear difference in complete clearance ‐ week 4 compared with oral ivermectin 200 μg/kg (2 doses) (high certainty).
1 finding from 1 review
1Sharma 2011. · people with scabies, over 5 years of ageLocation: India
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Intervention not reported
Overall survival## · patients with multiple myeloma
The intervention showed no clear difference in overall survival## (moderate certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival### · patients with multiple myeloma
The intervention showed no clear difference in progression‐free survival### (low certainty).
1 finding from 1 review